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 Synthesis and Cytotoxic Activity of Novel 3-methyl-
1-[(4-substitutedpiperazin-1-yl)methyl]-1 H -indole 
Derivatives
potent anticancer agents have been reported 
 [ 7 ,  9 – 11 ] . A series of small indole containing 
drugs and clinical candidates are given in   ●  ▶   Fig. 1 .
 Despite the fact that indole is core structure for 
inhibition of tubulin polymerization, numerous 
papers have also shown that Mannich base ana-
logs of heterocyclic rings exhibited potent cyto-
toxicity against several human tumor cell lines 
 [ 12 – 18 ] . Dimmock and Kumar reviewed antican-
cer and cytotoxic properties of Mannich bases 
and outlined the eff ects of these compounds on 
anticancer activity  [ 19 ] .
 Based on these prior observations, we designed 
new Mannich base analogues of 3-methylindole 
and aimed to evaluate their in vitro anticancer 
screening data against diff erent cancer cell lines.
 Materials and Methods
 ▼
 Chemistry
 All chemicals and reagents used in current study 
were analytical grade. The reactions were moni-
tored by thin layer chromatography (TLC) on 
Merck pre-coated silica GF254 plates. Melting 
points were determined by using a Mettler 
Toledo FP62 capillary melting point apparatus 
(Mettler-Toledo, Greifensee, Switzerland) and are 
 Introduction
 ▼
 Cancer treatment has been a major attempt of 
research in academia and pharmaceutical indus-
try for many years as it is one of the leading 
causes of death  [ 1 ,  2 ] . Recent drug discovery 
eff orts are highly focused towards design and 
synthesis of small molecules as anticancer agents 
due to the advantages of easier synthesis and 
lower cost. A wide variety of heterocyclic sys-
tems have been explored for the development of 
novel chemical entities as a lead molecule in 
anticancer drug discovery  [ 3 – 5 ] .
 Microtubules, one of the basic components of cell 
structure, are involved in a wide number of vital 
cellular functions, such as motility, division, shape 
maintenance and cellular transport  [ 6 ] . The 
research for novel drugs that can modulate the 
microtubule assembly either by inhibition of 
tubulin polymerization or by blocking microtu-
bule disassembly are of great interest in antican-
cer therapy. Vincristine and vinblastine are among 
the earliest antitumor agents recognized as tubu-
lin polymerization inhibitors since 1965  [ 7 ] .
 The indole ring is represented as the core nucleus 
of several tubulin polymerization inhibitors 
 [ 7 ,  8 ] . In the last decade, an increasing number of 
small synthetic molecules with indole ring as 
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 Abstract
 ▼
 A series of novel 3-methyl-1-[(4-substitutedpi-
perazin-1-yl)methyl]-1 H -indoles ( 3a–l) were syn-
thesized and their cytotoxicities were analyzed 
against 3 diff erent human cell lines, including 
liver (HUH7), breast (MCF7) and colon (HCT116). 
The  Mannich reaction of 3-methylindole ( 1) with 
4-substitutedpiperazines ( 2) and formaldehyde 
resulted to the 3-methyl-1-[(4-substitutedpiper-
azin-1-yl)methyl]-1 H -indoles ( 3a–l) in 38–69 % 
yields. The investigation of anticancer screening 
revealed that the tested compounds showed com-
parable activity to the reference drug 5-fl uorour-
acil and compounds  3g ,  3h ,  3i and  3k, had lower 
50 % inhibition (IC 50 ) concentration than refer-
ence drug. Moreover, the cytotoxic eff ect of the 
most potent compound  3h on HUH7 and MCF7 
cells through apoptosis was visualized by Hoechst 
staining and compared with paclitaxel, which is a 
mitotic inhibitor acting on microtubules. The mor-
phological features of apoptosis were observed as 
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uncorrected. Infrared spectra were recorded on a Perkin-Elmer 
Spectrum One series FT-IR apparatus (Version 5.0.1) (Perkin 
Elmer, Norwalk, CT, USA), using potassium bromide pellets, the 
frequencies were expressed in cm  − 1 . The  1 H- and  13 C-NMR spec-
tra were recorded with a Varian Mercury-400 FT-NMR spec-
trometer (Varian, Palo Alto, CA, USA), using tetramethylsilane as 
the internal reference, with chloroform-CDCl 3 as solvent, the 
chemical shifts were reported in parts per million (ppm) and 
coupling constants ( J ) were given in hertz (Hz). Elemental analy-
ses were performed on LECO 932 CHNS instrument (Leco-932, 
St. Joseph, MI, USA) and were within ± 0.4 % of the theoretical 
 values.
 General procedure for the synthesis of 3-methyl-1-[(4-
substitutedpiperazin-1-yl)methyl]-1H-indoles (3a–3l)
 A mixture of 3-methylindole  (1) (0.39 g, 0.003 mol), the appro-
priate N-substituted amine  (2) (0.003 mol) and 37 % formalde-
hyde solution (1 mL) in ethanol (15 mL), was refl uxed for 3–5 h. 
The crude products were either precipitated or it was necessary 
to add water in case not precipitated. The crude products were 




 Yield: 69 %; m. p.: 160.2 °C. IR (KBr) ν (cm  − 1 ): 3 054–2 797 (C-H). 
 1 H NMR (CDCl 3 , 400 MHz) δ (ppm): 7.56 (d, 1 H, indole H 4 , 
 J = 11.6), 7.43 (d, 1 H, indole H 7 ,  J = 8), 7.25-7.20 (m, 3 H, indole 
H 5 +phenyl H 2 , H 6 ), 7.12 (t, 1 H, indole H 6 ,  J = 8), 6.95 (s, 1 H, indole 
H 2 ), 6.88-6.82 (m, 3 H, phenyl H 3 , H 4 , H 5 ), 4.81 (s, 2 H, N-CH 2 -N), 
3.17 (t, 4 H, piperazine H 3, H 5 ,  J =  5.2), 2.69 (t, 4 H, piperazine H 2 , 
H 6 ,  J =  5.2), 2.33 (s, 3 H, -CH 3 ). Anal. calcd. for C 20 H 23 N 3 (305.42): 
C, 78.65; H, 7.59; N, 13.76. Found: C, 78.57; H, 7.56; N, 13.60.
 1-{[4-(2-Fluorophenyl)piperazin-1-yl]methyl}-3-methyl-
1H-indole ( 3b )
 Yield: 60 %; m. p.: 120.2 °C. IR (KBr) ν (cm  − 1 ): 3 045–2 788 (C-H). 
 1 H NMR (CDCl 3 , 400 MHz) δ (ppm): 7.56 (d, 1 H, indole H 4 ,  J = 7.6), 
7.43 (d, 1 H, indole H 7 ,  J = 8.4), 7.22 (t, 1 H, indole H 5 ,  J = 8.0), 7.12 
(t, 1 H, indole H 6 ,  J = 6.8), 7.05-6.88 (m, 5 H, indole H 2 +phenyl), 
4.81 (s, 2 H, N-CH 2 -N), 3.08 (t, 4 H, piperazine H 3, H 5 ,  J = 4.8), 2.72 
(t, 4 H, piperazine H 2 , H 6 ,  J = 4.8), 2.33 (s, 3 H, -CH 3 ). Anal. calcd. 
for C 20 H 22 FN 3 (323.41): C, 74.28; H, 6.86; N, 12.99. Found: C, 
74.24; H, 6.89; N, 12.98.
 1-{[4-(4-Fluorophenyl)piperazin-1-yl]methyl}-3-
methyl-1 H-indole (3c)  [ 20 ] 
 Yield: 51 %; m. p.: 109.5 °C. IR (KBr) ν (cm  − 1 ): 3 046–2 788 (C-H). 
 1 H NMR (CDCl 3 , 400 MHz) δ (ppm): 7.55 (d, 1 H, indole H 4 ,  J = 8), 
7.43 (d, 1 H, indole H 7 ,  J = 8.8), 7.21 (t, 1 H, indole H 5 ,  J = 6.8), 7.12 
(t, 1 H, indole H 6 ,  J = 6.8), 6.93 (dd, 2 H, phenyl H 3 , H 5 ,  J = 6.0, 
 J ’ = 2.8), 6.90 (s, 1 H, indole H 2 ), 6.81 (dd, 2 H, phenyl H 2 , H 6 ,  J = 9.4, 
 J ’ = 4.4), 4.80 (s, 2 H, N-CH 2 -N), 3.08 (t, 4 H, piperazine H 3, H 5 , 
 J =  5.2), 2.69 (t, 4 H, piperazine H 2 , H 6 ,  J =  5.2), 2.33 (s, 3 H, -CH 3 ). 
 13 C NMR (CDCl 3 , 400 MHz) δ (ppm): 158.65, 156.27, 148.14, 
137.48, 129.17, 126.33, 121.92, 119.20, 118.25, 115.72, 111.15, 
110.01 (aromatics), 67.86 (C- C H 2 -N), 50.72 (piperazine C 3 , C 5 ), 
50.33 (piperazine C 2 , C 6 ), 9.83 (-CH 3 ). Anal. calcd. for C 20 H 22 FN 3 




 Yield: 42 %; m. p.: 95.4 °C. IR (KBr) ν (cm  − 1 ): 3 043–2 718 (C-H). 
 1 H NMR (CDCl 3 , 400 MHz) δ (ppm): 7.55 (d, 1 H, indole H 4 ,  J = 8.0), 
7.41 (d, 1 H, indole H 7 ,  J = 8.4), 7.21 (t, 1 H, indole H 5 ,  J = 8.0), 7.14–
7.09 (m, 2 H, indole H 6 +phenyl H 2 ), 6.93 (s, 1 H, indole H 2 ), 6.81–
6.69 (m, 3 H, phenyl), 4.78 (s, 2 H, N-CH 2 -N), 3.14 (t, 4 H, 
piperazine H 3, H 5 ,  J = 5.2), 2.65 (t, 4 H, piperazine H 2 , H 6 ,  J = 5.2), 
2.32 (s, 3 H, -CH 3 ). Anal. calcd. for C 20 H 22 ClN 3 (339.86): C, 70.68; 
H, 6.52; N, 10.43. Found: C, 70.41; H, 6.65; N, 10.38.
 1-{[4-(4-Chlorophenyl)piperazin-1-yl]methyl}-3-
methyl-1 H-indole (3e)
 Yield: 58 %; m. p.: 144.1 °C. IR (KBr) ν (cm  − 1 ): 3 041–2 794 (C-H). 
 1 H NMR (CDCl 3 , 400 MHz) δ (ppm): 7.56 (d, 1 H, indole H 4 ,  J = 7.6), 
7.41 (d, 1 H, indole H 7 ,  J = 8.4), 7.24–7.10 (m, 4 H, indole H 5 , 
H 6 +phenyl H 3 , H 5 ), 6.93 (s, 1 H, indole H 2 ), 6.76 (d, 2 H, phenyl H 2 , 
H 6 ,  J = 9.2), 4.79 (s, 2 H, N-CH 2 -N), 3.11 (t, 4 H, piperazine H 3, H 5 , 
 J = 5.2), 2.67 (t, 4 H, piperazine H 2 , H 6 ,  J = 5.2), 2.32 (s, 3 H, -CH 3 ). 
Anal. calcd. for C 20 H 22 ClN 3 (339.86): C, 70.68; H, 6.52; N, 10.43. 
Found: C, 70.56; H, 6.56; N, 10.39.
 1-{[4-(2-Methoxyphenyl)piperazin-1-yl]methyl}-3-
methyl-1 H-indole (3f)
 Yield: 53 %; m. p.: 114.5 °C. IR (KBr) ν (cm  − 1 ): 3 046–2 788 (C-H). 
 1 H NMR (CDCl 3 , 400 MHz) δ (ppm): 7.56 (d, 1 H, indole H 4 ,  J = 8.0), 
7.43 (d, 1 H, indole H 7 ,  J = 8.4), 7.21 (t, 1 H, indole H 5 ,  J = 7.6), 7.11 
(t, 1 H, indole H 6 ,  J = 6.8), 7.00-6.89 (m, 4 H, indole H 2 +phenyl H 3 , 
H 4 , H 5 ), 6.82 (d, 1 H, phenyl H 6 ,  J = 7.2), 4.82 (s, 2 H, N-CH 2 -N), 
 Fig. 1  Structure comparison of small indole 































 Koksal M et al. Cytotoxic Activity of Indole Derivatives … Arzneimittelforschung 2012; 62: 389–394
3.80 (s, 3 H, O-CH 3 ), 3.05 (bs, 4 H, piperazine H 3, H 5 ), 2.74 (t, 4 H, 
piperazine H 2 , H 6 ,  J = 4.8), 2.32 (s, 3 H, -CH 3 ). Anal. calcd. for 
C 21 H 25 N 3 O (335.44): C, 75.19; H, 7.51; N, 12.53. Found: C, 75.12; 
H, 7.40; N, 12.43.
 1-{[4-(3-Methoxyphenyl)piperazin-1-yl]methyl}-3-
methyl-1H-indole (3g)
 Yield: 57 %; m. p.: 111.6 °C. IR (KBr) ν (cm  − 1 ): 3 050–2 842 (C-H). 
 1 H NMR (CDCl 3 , 400 MHz) δ (ppm): 7.56 (d, 1 H, indole H 4 ,  J = 8.0), 
7.42 (d, 1 H, indole H 7 ,  J = 8.4), 7.24–7.10 (m, 3 H, indole H 5 , 
H 6 ,+phenyl H 2 ), 6.94 (s, 1 H, indole H 2 ), 6.49–6.38 (m, 3 H, phe-
nyl), 4.80 (s, 2 H, N-CH 2 -N), 3.76 (s, 3 H, O-CH 3 ), 3.16 (t, 4 H, pip-
erazine H 3, H 5 ,  J = 5.2), 2.67 (t, 4 H, piperazine H 2 , H 6 ,  J = 4.8), 2.32 
(s, 3 H, -CH 3 ). Anal. calcd. for C 21 H 25 N 3 O (335.44): C, 75.19; H, 
7.51; N, 12.53. Found: 75.18; H, 7.53; N, 12.45.
 1-{[4-(4-Cyanophenyl)piperazin-1-yl]methyl}-3-methyl-
1H-indole (3h)
 Yield: 48 %; m. p.: 139.5 °C. IR (KBr) ν (cm  − 1 ): 2 938–2 832 (C-H), 
2 211 (C≡N).  1 H NMR (CDCl 3 , 400 MHz) δ (ppm): 7.56 (d, 1 H, 
indole H 4 ,  J = 7.6), 7.44–7.39 (m, 3 H, indole H 7 +phenyl H 3 , H 5 ), 
7.21 (t, 1 H, indole H 5 ,  J = 7.2), 7.12 (t, 1 H, indole H 6 ,  J = 7.6), 6.91 
(s, 1 H, indole H 2 ), 6.74 (d, 2 H, phenyl H 2 , H 6 ,  J = 8.8), 4.78 (s, 2 H, 
N-CH 2 -N), 3.26 (t, 4 H, piperazine H 3, H 5 ,  J = 4.8), 2.63 (t, 4 H, pip-
erazine H 2 , H 6 ,  J = 4.8), 2.32 (s, 3 H, -CH 3 ).  13 C NMR (CDCl 3 , 
400 MHz) δ (ppm): 153.44, 137.44, 133.71, 129.20, 126.32, 
122.08, 120.30 (aromatics), 119.32 (-CN), 114.47, 111.30, 109.98, 
100.49 (aromatics), 67.74 (C- C H 2 -N), 50.21 (piperazine C 3 , C 5 ), 
47.21 (piperazine C 2 , C 6 ), 9.87 (-CH 3 ). Anal. calcd. for C 21 H 22 N 4 




 Yield: 48 %; m. p.: 134 °C. IR (KBr) ν (cm  − 1 ): 3 042–2 852 (C-H), 
1 332 (NO 2 ).  1 H NMR (CDCl 3 , 400 MHz) δ (ppm): 8.08 (d, 2 H, 
phenyl H 3 , H 5 ,  J = 9.6 ), 7.56 (d, 1 H, indole H 4 ,  J = 7.6), 7.42 (d, 1 H, 
indole H 7 ,  J = 8.4 ), 7.22 (t, 1 H, indole H 5 ,  J = 7.2), 7.15 (t, 1 H, 
indole H 6 ,  J = 7.6), 6.93 (s, 1 H, indole H 2 ), 6.74 (d, 2 H, phenyl H 2 , 
H 6 ,  J = 9.6), 4.82 (s, 2 H, N-CH 2 -N), 3.40 (t, 4 H, piperazine H 3, H 5 , 
 J = 4.8), 2.68 (t, 4 H, piperazine H 2 , H 6 ,  J = 4.8), 2.33 (s, 3 H, -CH 3 ). 
Anal. calcd. for C 20 H 22 N 4 O 2 (350.41): C, 68.55; H, 6.33; N, 15.99. 
Found: 68.71; H, 6.27; 15.94.
 3-Methyl-1-{[4-(4-methylphenyl)piperazin-1-yl]
methyl}-1 H-indole (3j)
 Yield: 45 %; m. p.: 117.3 °C. IR (KBr) ν (cm  − 1 ): 3 048–2 789 (C-H). 
 1 H NMR (CDCl 3 , 400 MHz) δ (ppm): 7.55 (d, 1 H, indole H 4 ,  J = 8.0), 
7.42 (d, 1 H, indole H 7 ,  J = 8.4), 7.21 (t, 1 H, indole H 5 ,  J = 7.6), 7.11 
(t, 1 H, indole H 6 ,  J = 6.8), 7.04 (d, 2 H, phenyl H 3 , H 5 ,  J = 8.4), 6.94 
(s, 1 H, indole H 2 ), 6.78 (d, 2 H, phenyl H 2 , H 6 ,  J = 8.4), 4.80 (s, 2 H, 
N-CH 2 -N), 3.11 (t, 4 H, piperazine H 3, H 5 ,  J = 4.8), 2.68 (t, 4 H, pip-
erazine H 2 , H 6 ,  J = 5.2), 2.32 (s, 3 H, -CH 3 ), 2.25 (s, 3 H, -CH 3 ). Anal. 
calcd. for C 21 H 25 N 3 (319.44): C, 78.96; H, 7.89; N, 13.15. Found: 
C, 79.28; H, 7.85; N, 12.97.
 3-Methyl-1-{[4-(2,3-dimethylphenyl)piperazin-1-yl]
methyl}-1H-indole (3k)
 Yield: 43 %; m. p.: 108.7 °C. IR (KBr) ν (cm  − 1 ): 3 053–2 785 (C-H). 
 1 H NMR (CDCl 3 , 400 MHz) δ (ppm): 7.57 (d, 1 H, indole H 4 ,  J = 7.6), 
7.45 (d, 1 H, indole H 7 ,  J = 8.0), 7.22 (t, 1 H, indole H 5 ,  J = 7.2), 7.15 
(t, 1 H, indole H 6 ,  J = 7.6), 7.05 (t, 1 H, phenyl H 5 ,  J = 6.8), 6.96 
(s, 1 H, indole H 2 ), 6.90 (d, 2 H, phenyl H 4 , H 6 ,  J = 8.8), 4.84 (s, 2 H, 
N-CH 2 -N), 2.88 (t, 4 H, piperazine H 3, H 5 ,  J = 4.4), 2.72 (bs, 4 H, 
piperazine H 2 , H 6 ), 2.34 (s, 3 H, -CH 3 ), 2.23 (s, 3 H, -CH 3 ), 2.14 
(s, 3 H, -CH 3 ). Anal. calcd. for C 22 H 27 N 3 (333.47): C, 79.24; H, 
8.16; N, 12.60. Found: C, 79.10; H, 8.11; N, 12.52.
 3-Methyl-1-{[4-(2-phenylethyl)piperazin-1-yl]methyl}-
1H-indole (3l)  [ 20 ] 
 Yield: 39 %; m. p.: 122.9 °C. IR (KBr) ν (cm  − 1 ): 3 022–2 763 (C-H). 
 1 H NMR (CDCl 3 , 400 MHz) δ (ppm): 7.54 (d, 1 H, indole H 4 ,   J = 8.0), 
7.41(d, 1 H, indole H 7 ,  J = 8.0), 7.28–7.16 (m, 6 H, indol 
H 5 +phenyl), 7.11 (t, 1 H, indole H 6 ,   J = 7.2), 6.92 (s, 1 H, indole H 2 ), 
4.76 (s, 2 H, N-CH 2 -N), 2.75 (m, 2 H, -CH 2 -C 6 H 5 ), 2.60-2.54 (m, 
10 H, -CH 2 -N), 2.31 (s, 3 H, -CH 3 ). Anal. calcd. for C 28 H 31 N 3 




 The human cancer cell lines were grown in Dulbecco’s Modifi ed 
Eagle’s Medium (DMEM), with 10 % fetal bovine serum (FBS) and 
1 % penicillin. They were incubated in 37  °C incubators contain-
ing 5 % CO 2 and 95 % air.
 NCI-60 Sulphorhodamine B (SRB) assay
 Cancer cells (range of 2 000 cells/well to 5 000 cells/well) were 
inoculated into 96-well plates in 200 μL of media and incubated 
in 37  °C incubators containing 5 % CO 2 and 95 % air. After a 24 h 
incubation period, one plate for each cell line was fi xed with 
100 μL of 10 % ice-cold trichloroacetic acid (TCA). This plate rep-
resents the behavior of the cells just prior to compound treat-
ment and is accepted as the time-zero plate. The compounds to 
be tested were solubilized in dimethyl sulfoxide (DMSO) to a 
fi nal concentration of 40 mM and stored at +4  °C. While treating 
the cells with the compounds, the corresponding volume of the 
compound was applied to the cell to achieve the desired drug 
concentration and diluted through serial dilution (40, 20, 10, 5, 
2.5 μM). After drug treatment, the cells were incubated in 37  °C 
incubators containing 5 % CO 2 and 95 % air for 72 h. Following the 
termination of the incubation period after drug treatment, the 
cells were fi xed with 100 μL 10 % ice-cold TCA and incubated in 
the dark at + 4 °C for 1 h. Then the TCA was washed away with 
ddH 2 O 5 times and the plates were left to air dry. In the fi nal 
step, the plates were stained with 100 μL of 0.4 % SRB 
(cat.86183-5 g from Sigma) solution in 1 % acetic acid solution. 
Following staining, the plates were incubated in dark for 10 min 
at room temperature. The unbound dye was washed away using 
1 % acetic acid and the plates were left to air dry. To measure the 
absorbance results, the bound stain was then solubilized using 
200 μL of 10 mM Tris-Base. Camptothecin was the positive con-
trol and 5-Fluorouracil (5-FU) was standard drug for the cyto-
toxic eff ect. The OD values were obtained at 515 nm.
 Hoechst staining
 Apoptotic morphological alterations were visualized by Hoechst 
33258 staining under fl uorescent microscope. Cells were inocu-
lated into 6-well plates (60 000cell/well) and incubated for 24 h. 
Then, they were treated with solvent DMSO,  3 h or paclitaxel and 
incubated for 72 h. Fixation of the cells were accomplished by 
methanol followed by Hoechst 33258 staining. Finally, cells were 
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 Results and Discussion
 ▼
 Chemistry
 The target 3-methyl-1-[(4-substitutedpiperazin-1-yl)methyl]-
1 H -indole derivatives ( 3a–l) have been prepared by Mannich 
reaction between indole and appropriate piperazines (  ●  ▶   Fig. 2 ). 
Although 2 of compounds were registered in literature by our 
lab group for sigma receptor binding studies  [ 20 ] , for the entirety 
of the 3-methyl-1-substitutedindole group, data for them are 
given again.
 The prepared Mannich bases showed IR bands at 3 054–2 832 
cm  − 1 (C-H) for all derivatives and a typical nitrile band at 
2 211 cm  − 1 for Compound  3 h . In the  1 H NMR spectra, the signals 
of the respective protons of the prepared compounds  3a–l were 
verifi ed on the basis of their chemical shifts, multiplicities and 
coupling constants. General characteristic peaks of 3-methylin-
dole ring were observed at about δ 7.55 (d, 1 H, indole H 4 ) , 7.40 
(d, 1H, indole H 7 ) , 7.22 (t, 1H, indole H 5 ), 7.20 (t, 1H, indole H 6 ), 
6.90 (s, 1H, indole H 2 ), and 2.30 (s, 3H, -CH 3 ). The  1 H NMR spec-
tra of compounds  3a–l showed a singlet with 2H intensity each, 
in the range 4.84–4.76 ppm assigned to the methylene protons, 
confi rming the Mannich condensation. The chemical shift of the 
aliphatic protons of the piperazine ring were observed in the 
range 3.40–3.08 (t, 4H, piperazine H 3, H 5 ) and 2.72–2.63 ppm (t, 
4H, piperazine H 2 , H 6 ). In  13 C-NMR of  3c and  3 h signifi cant 
peaks at δ 67.74 (C- C H 2 -N), 50.21 (piperazine C 3 , C 5 ), 47.21 (pip-
erazine C 2 , C 6 ), 9.87 (-CH 3 ) were observed.
 Biological activity
 The cytotoxic activity of the synthesized compounds  3a–3l was 
investigated on liver (HUH7), breast (MCF7) and colon (HCT116) 
cancer cell lines, by means of sulphorhodamine B (SRB) assays in 
triplicate.
 As shown in   ●  ▶   Table 1 and   ●  ▶   Fig. 3 , all tested compounds were 
screened on 3 diff erent human cell lines with mean 50 % inhibi-
tion (IC 50 ) in micromolar concentration range. For liver cell line, 
HUH7, most of the compounds showed no activity at a concen-
tration higher than 100μM. However, it is interesting that com-
pounds with cytotoxic activity ( 3g ,  3h ,  3i and  3k ) exhibited 
better cell growth inhibition than standard drug 5-fl uorouracil 
(5-FU) with IC 50 values of 24.76, 14.38, 25.01 and 22.20 μM, 
respectively. The cytotoxic eff ects were not impressive against 
MCF7 breast cancer cells, all of the compounds showed cell via-
bility with IC 50 values ranging from 13.69–68.81 μM concentra-
tions. It was noteworthy that the cytotoxic eff ects were more 
pronounced against colon carcinoma cell line, HCT116. Similar to 
HUH7 cell line, compounds  3h (IC 50 = 8.75 μM),  3i (IC 50 = 15.91 μM) 
and  3k (IC 50 = 16.62 μM) have better IC 50 values than 5-FLU 
(IC 50 = 18.78 μM) and also compound  3h possessed 8.75 μM value, 
which represents good druggable cytotoxic activity.
 Considering the indole core structure of the compounds, we 
showed the cytotoxic eff ect of the most active compound  3h on 
HUH7 and MCF7 cells through apoptosis and compared with 
paclitaxel, which is a mitotic inhibitor acting on microtubules. 
Apoptotic morphological alterations were visualized by Hoechst 
33258 staining under fl uorescent microscope. The morphologi-
cal features of apoptosis, i. e., condensation of chromatin and 
fragmentation of the nucleus, were examined. DMSO treated 
control cells showed round and homogeneous nuclei, whereas 
 3h and paclitaxel treated-cells showed condensed and frag-
mented nuclei (  ●  ▶   Fig. 4 ).
 In order to study the structure-activity relationship (SAR), these 
results of activity screening are not clear enough, but on the 
other hand, some observations can be stated. Compound  3a 
with non-substituted phenyl indicated no cytotoxic activity 
against all 3 cell lines. Interestingly, the SAR study reveals that 
substitution on the phenyl ring plays an important role. Among 
the compounds,  3g ,  3h, 3i and  3k which have 3-OCH 3 , 4-CN, 
4-NO 2 and 2,3-diCH 3 substituents on phenyl ring showed better 
activity than 5-FLU. The activity results of these 4 compounds 
are almost parallel for both liver HUH7 and colon HCT116 cells. 
Generally, the derivatives carrying halogen on diff erent posi-
tions of phenyl exhibited moderate or low activity results; the 
only exception is compound  3b carrying  o -fl uoro substituent on 
phenyl ring for HCT116 cell line. The fi ndings for MCF7 repre-
 Fig. 2  Synthesis of compounds  3a–3l . 
 Table 1  Cytotoxic activity data for compounds  3a-l . 
 Compound  R  IC 50 (μM)* 
   HUH7  MCF7  HCT116 
 3a  Phenyl  NI  NI  NI 
 3b  2-Fluorophenyl  NI  23.30  14.48 
 3c  4-Fluorophenyl  NI  40.95  NI 
 3d  3-Chlorophenyl  NI  68.81  63.30 
 3e  4-Chlorophenyl  NI  64.73  64.55 
 3f  2-Methoxyphenyl  NI  41.29  26.88 
 3g  3-Methoxyphenyl  24.76  13.69  19.60 
 3 h  4-Cyanophenyl  14.38  23.48  8.75 
 3i  4-Nitrophenyl  25.01  NI  15.91 
 3j  4-Methylphenyl  NI  NI  28.15 
 3k  2,3-Dimethylphenyl  22.20  22.89  16.62 
 3 l  2-Phenylethyl  NI  26.23  23.86 
 CPT   0.15  > 0.01  > 0.01 
 5-FLU   30.70  3.50  18.78 
 *All the experiments were conducted in triplicate (1 <  R 2 < 0.8); 
 NI: no inhibition at a concentration lower than 100 μM; 
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sented that the compounds were inactive for breast carcinoma. 
Especially, in HUH7 liver cell line, although halogen substituted 
compounds had no cytotoxic activity, introduction of an elec-
tron rich substituent such as cyano, nitro to phenyl group have 
produced compounds with signifi cant IC 50 values.
 Conclusion
 ▼
 In conclusion, the present study showed that the synthesized 
compounds could be used as a part of a template for future 
development through modifi cation and derivatization to design 
 Fig. 3  Inhibitory eff ects of compounds on HUH7, 
MCF7 and HCT116 cell growth. 
 Fig. 4  The apoptotic eff ect of inhibitors on the 
morphology of the nuclear chromatin in HUH7 
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more potent anticancer compounds that carry indole core struc-
ture. As a preliminary work, this group representing 1-substi-
tuted indoles can build our research interest and experience in 
the discovery of novel promising antitumor agents. With combi-
nation of these and future indole-based series, a QSAR study can 
be valuable and these results may be helpful for extensive func-




 The chemistry part of this work was supported by a grant from 
The Scientifi c & Technological Research Council of Turkey 
(TUBITAK) (Project No. 108S009).
 Confl ict of Interest
 ▼
 The authors have declared no confl ict of interest.
 References
1  Waring  M J .  The Search for New Anticancer Drugs .   Dordrecht, The 
Netherlands :  Kluwer Academic Publishers ,  1992 ;  1 – 18 
2  Jemal  A ,  Siegel  R ,  Ward  E   et al.  Cancer statistics, 2008 .   CA Cancer J 
Clin  2008 ;  58 :  71 – 96 
3  Bacher  G ,  Beckers  T ,  Emig  P   et al.  New small-molecule tubulin inhibi-
tors .   Pure Appl Chem  2001 ;  73 :  1459 – 1464 
4  Buolamwini  J K ,  Addo  J ,  Kamath  S   et al.  Small molecule antagonists 
of the MDM2 oncoprotein as anticancer agents .   Curr Cancer Drug 
Targets  2005 ;  5 :  57 – 68 
5  Dass  C R ,  Choong  PF M .  Targeting of small molecule anticancer drugs to 
the tumour and its vasculature using cationic liposomes: lessons from 
gene therapy .   Cancer Cell International  2006 ;  6 :  17 
6  Downing  K H ,  Nogales  E .  Tubulin and microtubule structure .   Curr Opin 
Cell Biol  1998 ;  10 :  16 – 22 
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ity
 o
f L
iv
er
po
ol
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
